Specialty medications: traditional and novel tools can address rising spending on these costly drugs.

@article{Lotvin2014SpecialtyMT,
  title={Specialty medications: traditional and novel tools can address rising spending on these costly drugs.},
  author={A. Lotvin and W. Shrank and Surya C. Singh and Benjamin P. Falit and T. Brennan},
  journal={Health affairs},
  year={2014},
  volume={33 10},
  pages={
          1736-44
        }
}
Spending on specialty medications, which represented a small proportion of US pharmacy spending at the beginning of this decade, is growing by more than 15 percent annually. It is expected to account for approximately half ($235 billion) of total annual pharmacy spending by 2018. Among the numerous reasons for the high cost of this heterogeneous group of medications are the increasing size of target patient populations, the high cost of drug development, and a complex and uncoordinated delivery… Expand

Topics from this paper

Stemming the Escalating Cost of Prescription Drugs: A Position Paper of the American College of Physicians.
  • H. Daniel
  • Medicine
  • Annals of internal medicine
  • 2016
TLDR
Policy recommendations from the American College of Physicians to address the escalating costs of prescription drugs in the United States are reported and issues of regulatory approval, patents and intellectual property, assessment of value and cost-effectiveness, and health plan drug benefits are linked. Expand
Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings
TLDR
There has been a sharp increase in Medicare and out-of-pocket spending on topical steroids that is driven by higher costs for generics, and use of clinical decision support tools to enable substitution of the most affordable generic topical steroid from the corresponding potency class may reduce drug expenditures. Expand
Evaluation of Specialty Drug Price Trends Using Data from Retrospective Pharmacy Sales Transactions.
TLDR
There was a clear increase over the last few years of the study in the number of drugs with more than 10% annual increases in WAC, which has also shown a rebound after the economic crisis at the end of the last decade. Expand
Federal and Individual Spending on the 10 Costliest Medications in Medicare Part D from 2011 to 2015
TLDR
The publically available Medicare Part D usage data from 2011 to 2015 was reviewed to quantify the cost of the 10 costliest medications for Part D, evaluated the number of beneficiaries treated with these medications, and measured beneficiaries' out‐of‐pocket costs. Expand
Net Spending On Retail Specialty Drugs Grew Rapidly, Especially For Private Insurance And Medicare Part D.
TLDR
Although specialty drugs make up a small portion of retail prescriptions filled, it is found that they accounted for 37.7 percent of retail and mail-order prescription spending net of rebates in 2016-17, which tripled for Medicare Part D beneficiaries and more than doubled for people with private insurance. Expand
Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
  • S. Dusetzina, N. Keating
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
TLDR
Out-of-pocket costs for Medicare beneficiaries taking orally administered anticancer medications are high and will remain so after the doughnut hole closes, and efforts are needed to improve affordability of high-cost cancer drugs for beneficiaries who need them. Expand
The Present and the Future of Cost-Related Non-Adherence in Medicare Part D
TLDR
It is found that, compared to patients who do not use cost-saving strategies, those who do have 18–45 % increased odds of non-adherence to their medications, and the emergence of specialty medications as the key source of growth in benefit costs will likely increase the magnitude and direction of Musich’s findings. Expand
Share Of Specialty Drugs In Commercial Plans Nearly Quadrupled, 2003-14.
TLDR
From 2003 to 2014 the proportion of specialty prescription drugs (defined as those reimbursed at $600 or more per thirty-day fill) nearly quadrupled, as percentages of total drug fills and spending. Expand
Assessment of the Level of Satisfaction and Unmet Data Needs for Specialty Drug Formulary Decisions in the United States.
TLDR
It is believed that pharmaceutical manufacturers would be best able to satisfy the greatest clinical data unmet need, that is, head-to-head RCTs in specialty drug formulary decisions, despite a variety of data sources. Expand
Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
TLDR
Limiting out-of-pocket costs for expensive anticancer drugs like the IMiDs may improve access to oral therapy for patients with myeloma. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
TLDR
In 3-tier pharmacy benefit plans, prescribing generic or preferred medications within a therapeutic class is associated with improvements in adherence to therapy. Expand
Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums.
TLDR
In the vast majority of cases, coupons reduced monthly cost sharing to less than $250, a point at which patients were far less likely to abandon therapy with biologic anti-inflammatory drugs or with drugs for multiple sclerosis, but by reducing cost sharing, coupons may also circumvent efforts to encourage patients to use the most cost-effective drugs. Expand
Benefit design and specialty drug use.
TLDR
Examination of spending by privately insured patients with four conditions often treated with specialty drugs finds that specialty drug use is largely insensitive to cost sharing, with price elasticities ranging from 0.01 to 0.21. Expand
Pharmaceutical step-therapy interventions: a critical review of the literature.
  • B. Motheral
  • Medicine
  • Journal of managed care pharmacy : JMCP
  • 2011
TLDR
The research demonstrates that ST programs for therapy classes other than antipsychotics can provide significant drug savings through the greater use of lower-cost alternatives and, to a lesser extent, reduced drug utilization. Expand
Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
TLDR
The prospects for significant cost savings from the use of biosimilars appear to be limited for the next several years, but their use should increase over time because of both demand- and supply-side factors. Expand
Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective.
TLDR
Broadly implemented clinical pathways can achieve reasonable physician compliance, resulting in substantial cost savings, according to a first comprehensive evaluation of a pathways program implemented on a broad scale. Expand
Cancer's next frontier: addressing high and increasing costs.
TLDR
There remains widespread consensus that major changes in the health care delivery system are needed in order to align incentives and reduce the growth rate of health care spending, as well as promising proposals for delivery system reform. Expand
Episode-based payment for cancer care: a proposed pilot for Medicare.
TLDR
A framework for "episode-based" payment during chemotherapy treatment is proposed, which would cover the costs of drugs and their administration for a predefined period of treatment and would have the potential to reduce costs and improve patient outcomes. Expand
Pricing and Reimbursement in U.S. Pharmaceutical Markets
In this survey chapter on pricing and reimbursement in U.S. pharmaceutical markets, we first provide background information on important federal legislation, institutional details regardingExpand
Prescription drug spending trends in the United States: looking beyond the turning point.
TLDR
Trends are documented and underlying components are identified: declines in the role of blockbuster drugs, increased importance of biologics and vaccines relative to traditional pharmaceuticals, and a changing medication mix away from those prescribed principally by primary care physicians toward those mostly prescribed by specialists. Expand
...
1
2
3
...